Table 3.

The degradation of C3 fragments following deposition via the AP and CP (means ± SD)

	Anti-C3c: Anti-C3d reactivity ratio (R)	Estimated % C3b/iC3b degradation*
NHS	0.391 ± 0.061: 1	72.2 ± 4.3
NHS + anti-FD	0.166 ± 0.033: 1	88.2 ± 2.4
NHS + Mg/EGTA	0.709 ± 0.021: 1	49.6 ± 1.3
Raji cells in NHS†	1.41 ± 0.41: 1	0

^*% degradation of C3b/iC3b = 100 × (1–R_{B cells}/R_{Raji cells}).

^†see ref. 13.

The net MFI signals observed with anti-human C3c and -C3d on B lymphocytes, following in vitro complement activation of peripheral B lymphocytes as described in Table 1, were expressed as a C3c: C3d ratio for each of the five experiments performed with separate donors.